Artivion to Participate in Upcoming Investor Conferences
Get Alerts AORT Hot Sheet
Join SI Premium – FREE
ATLANTA, Aug. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.
Artivion's management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 9:30 a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
Members of the management team will also participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Monday, August 15, 2022 & Tuesday, August 16, 2022. Due to the format of this event no webcast will be available.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.
Contacts: | |
Artivion | Gilmartin Group LLC |
D. Ashley Lee | Brian Johnston / Lynn Lewis |
Executive Vice President & | Phone: 332-895-3222 |
Chief Financial Officer | |
Phone: 770-419-3355 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-to-participate-in-upcoming-investor-conferences-301598835.html
SOURCE Artivion, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- World's First Autonomous Humanoid Tennis Match: GALBOT Robots Complete 100+ Consecutive Rallies
- HTX Research Examines U.S. AI Equities: Technology Remains Early, While Capital Expenditure and Valuations Have Entered the Late Cycle
- Top Meme Coin To Buy: Pipedog Selling Persists Despite 3,294% APY as AlphaPepe Stage 20 Keeps Filling
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Needham & Company, Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share